CKD Bio Corporation

Quick facts

Phase 3 pipeline

• CKDB-501A · Diabetes
  CKDB-501A is a small molecule that targets the SGLT2 receptor.

Phase 1 pipeline

• Botox®50U
• CKDB-501B

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• CKD Bio Corporation portfolio CI brief
• CKD Bio Corporation pipeline updates RSS